Managing Your Care
642 articles
The Future of Pancreatic Cancer Treatment
Dr. Anil Rustgi discusses the latest developments in pancreatic cancer treatment and the direction of current research in early detection.
Symptoms and Risk Factors
Moderator Daniel G Garza leads Dr. Rachna Shroff and Dr. Fiyinfolu Balogun in a discussion of risk factors and symptoms of pancreatic cancer.
mRNA Vaccine Shows Promising Results
Dr. Vinod Balachandran is testing an mRNA vaccine for pancreatic cancer using the same technology as COVID vaccines.
Masks On: Prevent COVID-19 Spread
The CDC recommends that everyone wear cloth masks or coverings over their mouths and noses when out in public, to prevent the spread of COVID-19.
Terms of Use
Copyright The entire content included in this Website, letswinpc.org, including but not limited to text, graphics, or code, is copyrighted as a collective work under the United States’ and other copyright laws, and is the property of Let’s Win. The collective work includes works that are licensed to Let’s Win. ALL RIGHTS RESERVED. You may […]
Maintenance Chemotherapy Trial for Pancreatic Cancer Patients with the BRCA Mutation
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.
Financial Statements
Our organization maintains full transparency with you, our supporters, about how we spend your money. View Audited Financial Statements: View IRS Forms 990: Sign Up for Our Newsletter Receive articles and news immediately in your inbox by signing up for our newsletter.
A New Drug Combination to Control Advanced Pancreatic Cancer
A clinical trial for pancreatic cancer patients with the BRCA mutation tests the effectiveness of standard treatment plus a PARP inhibitor.
Comparing a Standard Chemotherapy With and Without a PARP Inhibitor
A clinical trial compares standard chemotherapy with and without the addition of a PARP inihibitor, for patients whose pancreatic cancer is spreading again.
Treating BRCA-Negative Pancreatic Cancer Patients with a Family Cancer History Similar to BRCA Carriers
A clinical trial looks at the effectiveness of a PARP inhibitor in BRCA-negative pancreatic cancer patients with a family history BRCA-type cancers.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.